BELLSHILL, SCOTLAND: LINK (www.linktech.co.uk), the innovative developer and manufacturer of nucleic acid reagents, announces the appointment of Dr Marc Lemaître as Chairman of the Board with immediate effect. He takes over office from Dr Mick McLean, who is standing down after 9 successful years in the role. Dr Lemaître will oversee LINK’s continued growth in developing both its established nucleic acid reagents business and expanding its range of innovative reagents for oligo therapeutics and diagnostics.

Since obtaining a PhD in Biochemistry from the University of Liège, Dr Lemaître has been working in the field of nucleic acids for over 30 years, holding senior positions within various high profile CMOs, Pharma and Biotech companies. He oversaw the implementation of IVD oligo production at Eurogentec, and worked for Glen Research before being appointed in 2009 as CEO and President of Girindus America. After negotiating the merger between Nitto-Denko Avecia and the US operations of Girindus in 2013